Global Type 1 Diabetes Market Size, Share, and COVID-19 Impact Analysis, By Device Type (Insulin Pen, Insulin Syringe, Insulin Pump, and Insulin Jet Injectors), By Insulin Type (Long-Acting Insulin, and Rapid-Acting Insulin), By End User (Homecare Settings, Hospitals & Clinics, Academic & Research Institutes, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Type 1 Diabetes Market Insights Forecasts to 2035

• The Global Type 1 Diabetes Market Size Was Estimated at USD 16.01 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 6.34% from 2025 to 2035
• The Worldwide Type 1 Diabetes Market Size is Expected to Reach USD 31.48 Billion by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Spherical Insights and Consulting, The Global Type 1 Diabetes Market Size was worth around USD 16.01 Billion in 2024 and is predicted to grow to around USD 31.48 Billion by 2035 with a compound annual growth rate (CAGR) of 6.34% from 2025 to 2035. The type 1 diabetes market offers opportunities in innovative insulin delivery systems, continuous glucose monitoring, digital health integration, biosimilars, personalized treatments, and rising global incidence, driving demand for advanced management solutions. 

Global Type 1 Diabetes Market Forecast and Revenue Outlook

• 2024 Market Size: USD 16.01 Billion
• 2035 Projected Market Size: USD 31.48 Billion
• CAGR (2025-2035): 6.34%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

Market Overview   

The term "type 1 diabetes market" refers to the diverse global industry encompassing prescription drugs, medical equipment, and biotechnological advancements aimed at diagnosing, treating, and potentially curing type 1 diabetes mellitus, an autoimmune disease characterized by complete insulin insufficiency and a permanent reliance on exogenous insulin supplementation. According to the NIH, the Special Statutory Funding Program for Type 1 Diabetes Research, known as the Special Diabetes Program, continues to support ground-breaking research aimed at preventing and curing Type 1 diabetes. Administered by NIDDK on behalf of the Department of Health and Human Services, it involves collaboration with NIH Institutes, the CDC, and guidance from the Diabetes Mellitus Interagency Coordinating Committee. Technology developments in insulin delivery devices and growing awareness of diabetes self-care and management are some important factors supporting the type 1 diabetes market. One of the main factors driving the market expansion for type 1 diabetes is the rising incidence of obesity and physical inactivity. The market for type 1 diabetes is expanding due in large part to technological advancements. Syringe-based insulin injections were the norm for treatment.

Key Market Insights

• North America is expected to account for the largest share in the type 1 diabetes market during the forecast period.
• In terms of device type, the insulin pen segment is projected to lead the type 1 diabetes market throughout the forecast period  
• In terms of insulin type, the long-acting insulin segment captured the largest portion of the market
• In terms of end user, the hospitals & clinics segment captured the largest portion of the market   

Type 1 Diabetes Market Trends

• Increased use of continuous glucose monitoring (CGM) devices, which allow for real-time tracking and lessen reliance on finger-prick testing.
• Insulin pumps and closed-loop/hybrid artificial pancreas devices are being used more frequently to automate insulin delivery in response to glucose measurements.
• Increased incidence, better healthcare infrastructure, and affordability are driving market expansion in Asia-Pacific and other emerging regions.
• Improved illness management and earlier diagnosis are being facilitated by increased awareness, education, and screening initiatives.   

Report Coverage

This research report categorizes the type 1 diabetes market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyzes the key growth drivers, opportunities, and challenges influencing the type 1 diabetes market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the type 1 diabetes market.  

Driving factors

The market for type 1 diabetes in Europe has grown as a result of rising consumer spending on healthcare and technological developments in the field. Technological developments in remote blood glucose monitoring systems are probably going to fuel the type 1 diabetes market's expansion globally. For increased accuracy, newer pump versions can be linked to continuous glucose monitoring devices and managed remotely using companion smartphone apps. Technological developments in insulin administration methods for patients with type 1 and type 2 diabetes have contributed to the type 1 diabetes market.    

Restraining Factor  

The market for type 1 diabetes is hampered by factors such as high treatment costs, restricted access to cutting-edge technology in low-income areas, a lack of knowledge, and regulatory barriers, all of which impede fair access, prompt diagnosis, and the broad adoption of novel treatments.

Market Segmentation   

The global type 1 diabetes market is divided into device type, insulin type, and end user.

Global Type 1 Diabetes Market, By Device Type:  

• The insulin pen segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.       

Based on device type, the global type 1 diabetes market is segmented into insulin pen, insulin syringes, insulin pumps, and insulin jet injectors. Among these, the insulin pen segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. Insulin pens offer a quicker, more discreet, and easier way to administer insulin than syringes. Insulin pens are also helpful for administering insulin when on the road due to their portable form. Without needing to carry syringes, vials, or other equipment, users can conveniently take insulin dosages as needed using pre-filled pens.     

The insulin pump segment in the type 1 diabetes market is expected to grow at the fastest CAGR over the forecast period. The insulin pump market is expanding at the quickest rate among Type 1 diabetics because of its capacity to supply insulin continuously and precisely, simulating the normal function of the pancreas. Glycemic control and patient convenience are improved by developments in pump technology, including as automated insulin delivery and integration with continuous glucose monitoring (CGM) devices.  

Global Type 1 Diabetes Market, By Insulin Type:

• The long-acting insulin segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.      

Based on the insulin type, the global type 1 diabetes market is segmented into long-acting insulin, and rapid-acting insulin. Among these, the long-acting insulin segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Long-acting insulin maintains baseline insulin levels steady overnight and between meals because it stays in the bloodstream for a long time. This consistent insulin coverage avoids both high and low blood sugar levels by simulating the body's natural insulin secretion. Patients with Type 1 Diabetes who require continuous pump infusion or multiple daily injections are therefore better off using long-acting insulin.    

The rapid-acting insulin segment in the type 1 diabetes market is expected to grow at the fastest CAGR over the forecast period. The growing need for better post-meal blood sugar control and continuous advancements in insulin formulations that provide quicker onset and enhanced patient convenience are driving the rapid-acting insulin market.

Global Type 1 Diabetes Market, By End User:

• The hospitals & clinics segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.      

Based on end user, the global type 1 diabetes market is segmented into homecare settings, hospitals & clinics, academic & research institutes, and others. Among these, the hospitals & clinics segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The hospitals and clinics sector is mainly because of the vital role that these medical facilities play in type 1 diabetes diagnosis, treatment, and long-term care. Comprehensive care is provided by hospitals and clinics, which also provide access to skilled endocrinologists, cutting-edge diagnostic equipment, and a variety of treatment choices, including insulin therapy and diabetes education.  

The homecare settings segment in the type 1 diabetes market is expected to grow at the fastest CAGR over the forecast period. The growing demand from patients for easy-to-use at-home diabetes care options is fueling the homecare settings market. Patients can now manage their conditions more autonomously due to technological advancements, including smartphone-connected gadgets, continuous glucose monitoring, and portable insulin pumps. 

Regional Segment Analysis of the Global Type 1 Diabetes Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America Type 1 Diabetes Market Trends

North America is expected to hold the largest share of the global type 1 diabetes market over the forecast period.     

The market in North America is largely driven by the rise in type 1 diabetes patients, including children and adolescents. Innovations in insulin delivery, high diagnosis rates, strong reimbursement policies, and diagnostics all support the North American region. Improvements in CGMs, insulin formulations, CGM-integrated pumps, and improved healthcare infrastructure further solidify North America's dominant position in the Type 1 Diabetes market. Medtronic’s MiniMed 780G received FDA clearance in September 2025 for integration with Abbott’s Instinct Sensor, advancing automated insulin delivery. Tandem Diabetes Care also introduced the rechargeable Sigi patch pump at ADA 2025, highlighting continued innovation in diabetes technology.  

U.S Type 1 Diabetes Market Trends

The U.S. dominates the North American market because of things like favorable reimbursement policies for innovative therapies, high levels of awareness regarding diabetes management, and rising healthcare costs. The growing use of insulin pumps, continuous glucose monitors (CGMs), and digital health solutions that improve patient outcomes and disease management is also supporting the medical device market.

Canada Type 1 Diabetes Market Trends

The market for Type 1 Diabetes in Canada is expanding gradually as a result of rising diabetes management awareness and disease prevalence. Demand is being driven by technological innovations like insulin pumps and continuous glucose monitors. Government programs and financing for diabetes treatment also contribute to the market's expansion.

Asia Pacific Type 1 Diabetes Market Trends

Asia Pacific is expected to grow at the fastest CAGR in the type 1 diabetes market during the forecast period.  

In Asia Pacific, diabetes support groups and associations are also actively developing education and awareness campaigns to identify and treat Type 1 Diabetes early. The WHO South-East Asia Region's Colombo Call to Action in November 2024, which committed to improved diabetes preventive and control efforts among member states, is one example of a government declaration that supports this trend. Important diabetic treatments were added to the World Health Organization's Essential Medicines List in September 2025, allowing for easier access in low- and middle-income nations.

Japan Type 1 Diabetes Market Trends

Growing awareness and better diagnosis techniques are driving the Type 1 Diabetes industry in Japan. Disease management is being improved by the use of cutting-edge technologies like insulin pumps, continuous glucose monitoring (CGM) devices, and digital health platforms. Better patient access to cutting-edge treatments is being promoted by government assistance through healthcare regulations and payment programs.  

China Type 1 Diabetes Market Trends

Improved diagnosis, growing healthcare awareness, and rising disease prevalence are all contributing to the Type 1 Diabetes market's notable expansion in China. The increasing number of patients is a result of rapid urbanization and lifestyle changes.  Government programs to improve the infrastructure for diabetes care are lending support to the growing use of advanced technology like insulin pumps, digital health platforms, and continuous glucose monitoring (CGM).  

Competitive Analysis:  

The report offers the appropriate analysis of the key organizations/companies involved within the global type 1 diabetes market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

Worldwide Top Key Players In The Type 1 Diabetes Market Include

• Adocia
• Sanofi
• Novartis
• Biocon Ltd.
• AstraZeneca
• Ypsomed AG
• Novo Nordisk
• Wockhardt Ltd.
• Diamyd Medical
• Zealand Pharma
• Eli Lilly and Company
• Anelixis Therapeutics
• Panbela Therapeutics
• Gan & Lee Pharmaceuticals
• Oramed Pharmaceuticals Inc.
• Others  

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent development

• In March 2025, Vertex Pharmaceuticals Incorporated announced the completion of enrolment and dosing in Parts A and B of the Phase 1/2 VX-264 study for type 1 diabetes. Part B involved full-dose pancreatic islet cell therapy encapsulated in a proprietary immunoprotective device, with the Day 90 analysis now underway.
• In November 2023, Sanofi launched a national education campaign called "The 1 Pledge" movement. Prominent celebrities, such as artist and philanthropist Usher Raymond IV, whose child was diagnosed with Type 1 Diabetes at an early age, will spearhead the "The 1 Pledge" initiative.
• In April 2023, Sanofi announced the completion of its acquisition of ProventionBio, adding TZIELD, a first-in-class Type 1 Diabetes medication, to its General Medicines portfolio, accelerating Sanofi’s strategic shift toward differentiated medicines.
• In March 2023, Lexicon Pharmaceuticals announced plans to reapply for FDA approval of sotagliflozin as a New Drug Application (NDA) to improve glycemic control in Type 1 Diabetes patients with chronic renal disease, targeting mid-2024 resubmission and six-month approval timeline.

Market Segment   

This study forecasts revenue at the global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the type 1 diabetes market based on the following segments:

 Global Type 1 Diabetes Market, By Device Type

• Insulin Pen
• Insulin Syringe
• Insulin Pump
• Insulin Jet Injectors

Global Type 1 Diabetes Market, By Insulin Type

• Long-Acting Insulin
• Rapid-Acting Insulin

Global Type 1 Diabetes Market, By End User

• Homecare Settings
• Hospitals & Clinics
• Academic & Research Institutes
• Others

Global Type 1 Diabetes Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa